Precision BioSciences (NASDAQ:DTIL) Earns “Buy” Rating from HC Wainwright

Precision BioSciences (NASDAQ:DTIL)‘s stock had its “buy” rating reiterated by HC Wainwright in a note issued to investors on Friday,Benzinga reports. They currently have a $60.00 price target on the stock.

Separately, BMO Capital Markets raised Precision BioSciences from a “market perform” rating to an “outperform” rating and set a $34.00 price objective on the stock in a research report on Friday.

Precision BioSciences Trading Up 26.7 %

DTIL stock opened at $5.70 on Friday. The stock has a market capitalization of $43.72 million, a price-to-earnings ratio of 95.02 and a beta of 1.41. Precision BioSciences has a twelve month low of $3.61 and a twelve month high of $19.43. The firm’s fifty day simple moving average is $6.09 and its two-hundred day simple moving average is $8.26. The company has a quick ratio of 9.22, a current ratio of 9.22 and a debt-to-equity ratio of 0.34.

Institutional Investors Weigh In On Precision BioSciences

An institutional investor recently raised its position in Precision BioSciences stock. Janus Henderson Group PLC boosted its holdings in shares of Precision BioSciences, Inc. (NASDAQ:DTIL) by 10.9% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 702,069 shares of the company’s stock after acquiring an additional 68,943 shares during the period. Janus Henderson Group PLC owned about 9.15% of Precision BioSciences worth $6,322,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 37.99% of the company’s stock.

About Precision BioSciences

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.